Second-line Ramucirumab Showcases Survival Benefits in HCC, Irrespective of Extrahepatic Spread
September 7th 2022Second-line treatment with ramucirumab produced an overall survival benefit vs placebo in Chinese patients with hepatocellular carcinoma, irrespective of the presence of extrahepatic spread, according to findings from an exploratory analysis of the phase 3 REACH and REACH-2 trials.
Sequential Combo of Regorafenib and Nivolumab Shows Manageable Safety in Sorafenib-Pretreated HCC
September 6th 2022The sequential treatment of regorafenib followed by nivolumab was found to have an acceptable toxicity profile in patients with hepatocellular carcinoma who progressed on and tolerated first-line sorafenib, according to early data from the phase 1/2a GOING trial.
Investigators Look to Overcome Resistance in Advanced HCC With Triplet Combinations
September 5th 2021Triplet regimens leveraging novel agents targeted at overcoming mechanisms of resistance in combination with immune checkpoint inhibitors and anti-angiogenic therapies represent the next frontier in hepatocellular carcinoma.
Atezolizumab/Bevacizumab Improves OS in Albumin-Bilirubin Grade 1 HCC
September 5th 2021The combination of atezolizumab and bevacizumab elicited an improved overall survival benefit compared with sorafenib in patients with albumin-bilirubin grade 1 hepatocellular carcinoma, according to findings from an exploratory subgroup analysis of the phase 3 IMbrave150 trial.
Dual Checkpoint Blockade/Ablation Regimens Show Intriguing Activity in Advanced HCC
September 4th 2021Combining durvalumab and tremelimumab plus transcatheter arterial chemoembolization or radiofrequency ablation was found to be both efficacious and safe as a treatment for patients with advanced hepatocellular carcinoma, according to results of a pilot study.
Dr. Cheng on the Need For Biomarkers in HCC
September 28th 2018Ann-Lii Cheng, MD, distinguished professor, Department of Internal Medicine, National Taiwan University College of Medicine Director, Graduate Institute of Oncology, director, Department of Medical Oncology, discusses the need for biomarkers in hepatocellular carcinoma.
Immunotherapy Combos May Shape the Future of HCC Therapy
September 17th 2018The development of novel immunotherapy combinations is among the most significant trends emerging as part of the next wave of discovery in hepatocellular carcinoma, with several promising regimens incorporating checkpoint inhibitors undergoing testing in phase III studies.
Dr. Kudo on Cost-Effectiveness Analysis of Lenvatinib Versus Sorafenib
September 16th 2018Masatoshi Kudo, MD, PhD, professor and chairman, Department of Gastroenterology and Hepatology, Kindai University, Osaka, Japan, discusses the results of a cost-effectiveness analysis of lenvatinib versus sorafenib in unresectable hepatocellular carcinoma in Japan.
Dr. Finn on Role of Lenvatinib in HCC Treatment Paradigm
September 16th 2018Richard Finn, MD, professor of clinical medicine in the Division of Hematology and Oncology, director of the Signal Transduction and Therapeutics Program at the Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at the University of California, Los Angeles, discusses the role lenvatinib (Lenvima) in the treatment paradigm for advanced hepatocellular carcinoma.
Independent Review Backs Key REFLECT Findings With Lenvatinib in HCC
September 16th 2018The positive outcomes that lenvatinib demonstrated as first-line therapy for patients with hepatocellular carcinoma are confirmed in an independent assessment conducted as part of the pivotal, international phase III REFLECT trial.
Dr. Cheng on Tumor Heterogeneity in HCC and Challenges for Clinical Trials
September 15th 2018Ann-Lii Cheng, MD, PhD, distinguished professor and director of the cancer center of National Taiwan University, discusses the challenges that tumor heterogeneity in hepatocellular carcinoma (HCC) pose for clinical trials.